APA (7th ed.) Citation

JE, M., MS, F., RKC, M., W, R., JP, L., A, D., . . . J, G. M. (2023). Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study. Infection control and hospital epidemiology, 44(7), 1171. https://doi.org/10.1017/ice.2023.17

Chicago Style (17th ed.) Citation

JE, Mangino, Firstenberg MS, Milewski RKC, Rhys-Williams W, Lees JP, Dane A, Love WG, and Gonzalez Moreno J. "Exeporfinium Chloride (XF-73) Nasal Gel Dosed over 24 Hours Prior to Surgery Significantly Reduced Staphylococcus Aureus Nasal Carriage in Cardiac Surgery Patients: Safety and Efficacy Results from a Randomized Placebo-controlled Phase 2 Study." Infection Control and Hospital Epidemiology 44, no. 7 (2023): 1171. https://doi.org/10.1017/ice.2023.17.

MLA (9th ed.) Citation

JE, Mangino, et al. "Exeporfinium Chloride (XF-73) Nasal Gel Dosed over 24 Hours Prior to Surgery Significantly Reduced Staphylococcus Aureus Nasal Carriage in Cardiac Surgery Patients: Safety and Efficacy Results from a Randomized Placebo-controlled Phase 2 Study." Infection Control and Hospital Epidemiology, vol. 44, no. 7, 2023, p. 1171, https://doi.org/10.1017/ice.2023.17.